Gerber Kawasaki Wealth & Investment Management lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,779 shares of the biopharmaceutical company’s stock after selling 1,882 shares during the period. Gerber Kawasaki Wealth & Investment Management’s holdings in Gilead Sciences were worth $414,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of GILD. Welch Investments LLC purchased a new position in shares of Gilead Sciences during the third quarter worth $108,000. Wealthcare Advisory Partners LLC purchased a new position in Gilead Sciences in the third quarter valued at $133,000. Horan Capital Advisors LLC. purchased a new position in Gilead Sciences in the third quarter valued at $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Gilead Sciences in the second quarter valued at $147,000. Finally, Hanson & Doremus Investment Management increased its holdings in Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares in the last quarter. 77.83% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have weighed in on the stock. Barclays reaffirmed an “overweight” rating and issued a $95.00 price objective (up previously from $90.00) on shares of Gilead Sciences in a report on Tuesday, March 6th. BidaskClub cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $94.00 price objective on shares of Gilead Sciences in a report on Friday, February 23rd. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $80.00 price objective (down previously from $83.00) on shares of Gilead Sciences in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $88.61.
In related news, Director John Francis Cogan sold 5,833 shares of the business’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $80.93, for a total transaction of $472,064.69. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the transaction, the insider now owns 3,046,766 shares in the company, valued at $224,302,912.92. The disclosure for this sale can be found here. Insiders have sold 430,268 shares of company stock worth $34,074,395 over the last 90 days. 1.30% of the stock is currently owned by company insiders.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $77.18 on Tuesday. The firm has a market cap of $104,456.84, a PE ratio of 22.18, a P/E/G ratio of -1.83 and a beta of 1.24. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $89.54. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. Gilead Sciences’s quarterly revenue was down 18.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.70 earnings per share. analysts anticipate that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 2.95%. Gilead Sciences’s payout ratio is presently 65.52%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.